Tempest Therapeutics has gained an option to license a new in-body CAR-T technology from Senlang.
No additional details are provided about the terms of the agreement or the potential applications of the technology.
Key Takeaways
Center
Coverage blindspot: Reporting on this development is currently concentrated in other segments of the media landscape.
Coverage blindspot: Reporting on this development is currently concentrated in other segments of the media landscape.
Get every side of the week's biggest story in your inbox.
The technology could have implications for the treatment of certain diseases
No attributed perspective yet — we only show quotes grounded in analysis.
Evaluated across 1 reporting source (0% Left · 100% Center · 0% Right)
Historical editorial baseline for marketscreener.com
Multi-factor accuracy index for marketscreener.com and related desks based on verifiable sourcing and editorial standards.
Factuality: High 100%
Ownership: marketscreener.com (Corporate)
Public conversation related to this story
Loading comments…